Letter from Reckitt Benckiser VP for scientific and regulatory affairs -- baltimoresun.com

Subscribe Now

Road closures in effect for Baltimore marathon today
Marathon route | Archived marathon coverage | Official marathon Web site

E-mail this story

Letter from Reckitt Benckiser VP for scientific and regulatory affairs

Rolley "Ed" Johnson, vice president for scientific and regulatory affairs of Reckitt Benckiser Pharmaceuticals, Inc., responded in writing to some of the The Sun's findings about misuse of buprenrophine, a drug made by the company to treat opiate dependence.

December 17, 2007